A new drug, LCZ696, may mark a significant improvement in heart failure treatments. The drug acts as both an angiotensin receptor blocker and utilizes a neprilysin inhibitor, which limits the hormones that cause blood vessel constriction. Scott Solomon, professor of medicine at Brigham and Women’s Hospital, is quoted.
